WHO to List Exchange Programs in Cancer Ed

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 9
Volume 7
Issue 9

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE) is putting together a list of exchange programs in cancer education, (eg, exchange of students, residents, or faculty), involving a European or US center and a corresponding center in Asia, Africa, or Latin America.

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE) is putting together a list of exchange programs in cancer education, (eg, exchange of students, residents, or faculty), involving a European or US center and a corresponding center in Asia, Africa, or Latin America.

The INCE is sponsoring a symposium on such exchange programs on November 4-7, 1998, in Portland, Oregon, and is soliciting descriptions of such activities, comments, and ideas for future use, as well as abstracts of papers.

Physicians or institutions may contact Charles D. Sherman, Jr, MD, Highland Hospital, 1000 South Avenue, Rochester, NY 14620.

Articles in this issue
Intensive Effort Required to Develop a Breast Cancer Risk Assessment Clinic
NCI Readies Its Cancer Genetics Network for Collaborative Studies
Payer Relationships Key to Transplant Revenues
Taking Family Cancer History May Release Emotions
Ovarian Cortical Tissue Is Cryopreserved for Future Fertility
Advice Offered for Daughters of Women With Breast Cancer
WHO to List Exchange Programs in Cancer Ed
Women’s Groups Ask Congress for Global Tobacco Controls
Brain Tumor Patients Urged to ‘Seize Control’ of Their Seizures
UCSF Breaks Ground for Its New Clinical Cancer Building
Preventive Effects of Tamoxifen Vary With HER2 Level
NIH Expert Dispels Myths About Genetic Counseling
Advanced Colorectal Cancer Patients May Prefer Raltitrexed
FDG-PET Finds Residual, Recurrent Hodgkin's Disease
Ceprate Gets FDA Nod for Peripheral Blood Stem Cell Selection
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia

Russ Conroy
November 21st 2024
Article

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

Roman Fabbricatore
November 20th 2024
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.

Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC

Tim Cortese
November 20th 2024
Article

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.